This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
The Phase 2 clinical trial will analyze blood-based biomarkers versus conventional radiography for cancer patients treated with immunotherapy; findings could change direction of lung cancer treatment
The Cancer Research Institute (CRI) was informed on July 16, 2020, that one of our vendors, Blackbaud, experienced a data incident in May of this year.
30 days of immunotherapy education and awareness programming for patients, caregivers, and the others celebrating advances in immuno-oncology research and treatment
Report reveals that the cellular immunotherapy landscape continues to expand, with 472 more cellular therapies in development now than one year ago.
Results of recent survey of clinical trial investigators in United States, Europe, and Asia together with analysis of ongoing clinical trials conducted by IQVIA published in Nature Reviews Drug Discovery.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).